全数字化乳腺X线摄影联合彩色多普勒超声对诊断微小乳腺癌的研究

Objective To evaluate the efficacy of color Doppler sonography combined with digital mammography for micro breast cancer screening.Methods Both of color Doppler sonography and digital mammography were performed in 66 patients with micro breast cancer less than 1.5 cm in diameter and 20 patients with benign lesion less than 1.5 cm in diameter.The images of sonography and mammography were analyzed respectively.A comparative study on the results of sonography,mammography and pathological finding of specimen in breast lesions was made.Results Fifty-five of 66 Cases with micro breast cancer were detected by digital mammography.52 of 66 cases by color Doppler sonography and 65 of 66 cases by sonography combined with mammography.The color Doppler sonography combined with digital mammography provided higher sensitivity,specificity and accuracy[98.5%(65/66),100.0%(20/20)and 98.8%(85/86)respectively]than color Doppler sonography[78.8%(52/66),75.0%(15/20),77.9% (67/86)respectively]and digital mammography alone[83.3%(55/66),90.0%(18/20)and 84.9%(73/86)respectively](P＜0.05).The peak flow velocities and the mean resistant index were higher in malignant lesion than those in benign lesion(P＜0.05).Conclusions The color Doppler sonography combined with digital mammography can increase the sensitivity and accuracy of diagnosing micro breast cancer.Digital mammography is recommended to identify micro breast cancer.It is helpful of color Doppler sonography in differentiation of benign and malignant breast lesion.     

痰液癌胚抗原、癌抗原125、糖链抗原19-9和细胞角蛋白21-1片段检测对肺癌的诊断价值

目的 检测痰液中癌胚抗原(CEA)、癌抗原125(CA125)、糖链抗原19-9(CA19-9)和细胞角蛋白21-1片段(CYFRA21-1)的含量,探讨痰液中肿瘤标志物检测在肺癌诊断中的意义.方法 采用化学发光免疫分析法检测52例肺癌(肺癌组)和46例肺部良性病变患者(对照组)痰液中CEA、CA125、CA19-9和CYFRA21-1的含量.结果 肺癌组痰液中CEA、CA125、CA19-9和CYFBA21-1的含量分别为(27.6±31.2)μg/L、(76.4±65.2)kU/L、(56.1±31.6)kU/L和(25.2±9.1)μg/L;对照组分别为(6.1±7.5)μg/L、(23.7±7.9)kU/L、(17.3±10.2)kU/L和(1.2±1.7)μg/L,两组比较差异均有统计学意义(P<0.01).肺癌组痰液中CEA、CA125、CA19-9和CYFBA21-1的敏感度分别为42.3%(22/52)、46.2%(24/52)、36.5%(19/52)和51.9%(27,52),四种肿瘤标志物单项在肺癌中的敏感度比较差异均无统计学意义(P>0.05).腺癌CEA阳性率高于鳞癌(x2=4.193,P<0.05),CYFRA21-1阳性率低于鳞癌(x2=4.806,P<0.05).Ⅲ期+Ⅳ期肺癌患者CA125的阳性率较Ⅰ期+Ⅱ期高(x2=5.202,P<0.05).痰液中单项肿瘤标志物的检测阳性率不高,含CYFRA21-1的两项、三项、四项检测组合阳性率明显提高(P

Abstract：

Objective To evaluate the clinical significance of carcinoembryonic antigen (CEA),cancer antigen 125 (CA125),carbohydrate antigen 19-9 (CA19-9) and eytokeratin 21-1 fragment (CYFRA21-1) assays of sputum in patients with lung cancer. Method Fifty-two cases with lung cancer and 46 cases with benign lung diseases underwent detection of CEA ,CA125 ,CA19-9 and CYFRA21-1 in sputum by using the method of chemi-luminescent enzyme immunoassay. Results The levels of CEA,CA125,CA19-9 and CYFRA21-1 in sputum of 52 cases with lung cancer were (27.6±31.2) μg/L, (76.4±65.2)kU/L, (56.1±31.6) kU/L and ( 25.2±9.1 )μg/L respectively. But the levels of those of 46 cases with benign lung diseases were (6.1±7.5)μg/L, (23.7±7.9) kU/L, (17.3±10.2) kU/L and (1.2±1.7)μg/Lrespectively. The levels of these tumor markers in sputum in patients with lung cancer were significantly higher than those in patients with benign lung diseases(P< 0.01 ). The diagnostic sensitivity of CEA,CA125,CA 19-9 and CYFRA21-1 in sputum in 52 cases with lung cancer was 42.3%( 22/52 ), 46.2% (24/52), 36.5%( 19/52 ) and 51.9% (27/52) respectively ( P > 0.05 ). Among the cancer patients, the sensitivity of sputum CEA in patients with adenocareinoma was significantly higher than that in patients with squamons cell carcinoma (X2= 4.193, P < 0.05 ) ; while the sensitivity of sputum CYFRA21-1 in patients with squamous cell carcinoma was significantly higher than that in patients with adenocarcinoma ( X2 = 4.806,P < 0.05 ). The sensitivity of CA125 in advanced lung cancer( Ⅲ +Ⅳ stage) was higher than that in early lung cancer( Ⅰ+Ⅱstage) (X2= 5.202,P < 0.05 ). Compared with the single tumor marker assaying, the combination of CEA,CA 125, CA 19-9 and CYFRA21-1 in sputum could significantly improve the sensitivity and accurate value in the diagnosis of lung cancer (P<0.05). Conclusion To assay CEA,CA125,CA1g-9 and CYFRA21-1 in sputum is valuable in diagnosis of lung cancer, and the combination of CEA,CA125,CA19-9 and CYFRA21-1 in sputum can significantly improve sensitivity and accurate value in the diagnosis of lung cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

人血清激肽释放酶6在上皮性卵巢癌诊断及监测中的意义

Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.     

血清糖类抗原153、糖类抗原125、细胞角蛋白19片段联合彩色多普勒高频超声检查在早期乳腺癌诊断中的价值

目的探索血清肿瘤标志物糖类抗原(Carbohydrate antigen,CA) 153、CA125、细胞角蛋白19片段(cytokeratin19fragmentantigen21-1,CYFRA21-1)、彩色多普勒高频超声单独和联合检测在早期乳腺癌诊断中的价值。方法采用电化学发光法检测88例乳腺癌患者、142例乳腺良性疾病患者、200例健康女性的CA153、CA125、CYFRA21-1的水平,对3组受试者行乳腺彩色多普勒高频超声检查。结果乳腺癌组血清CA153、CA125、CYFRA21-1水平较乳腺良性病组和对照组明显升高,差异有统计学意义(P <0. 05);3项血清标志物联合检测的灵敏度为40. 9%,特异度为93. 7%;乳腺彩色多普勒高频超声检查的灵敏度为87. 5%,特异度为92. 3%;4项联合检测的灵敏度为93. 2%,特异度为91. 5%;4项联合检测的ROC曲线下面积(area under the curve,AUC)最大,AUC4项联合> AUC彩超> AUC3项血清标志物联合>AUCCA153> AUCCYFRA21-1> AUCCA125(P <0. 05)。结论单项血清CA153、CA125、CYFRA21-1检测对乳腺癌诊断价值不高,4项联合检测可以明显提高乳腺癌诊断的灵敏度,对乳腺癌早期诊断有重要的临床价值。     

彩色多普勒高频超声与血清肿瘤标志物联合诊断小乳腺癌的临床价值

目的：探讨彩色多普勒高频超声与血清肿瘤标志物联合诊断小乳腺癌的临床价值研究。方法：对1200例乳腺彩色多普勒高频超声发现实性肿块,经超声测量直径≤2.0 cm的患者进行血清肿瘤标志物CYFRA21-1、CA15-3及TSGF检查,并追踪手术病理结果,统计两种检查方法联合检验对诊断乳腺癌的灵敏度、特异性及准确率。结果：单独乳腺高频超声检查对诊断乳腺癌的灵敏度87.2%,特异性83.8%,准确率84.5%;单独血清肿瘤标志物对诊断乳腺癌的灵敏度84.1%,特异性81.4%,准确率82.0%,而高频超声和血清肿瘤标志物联合检测的灵敏度、特异性和准确率分别是91.8%、91.5%和90.7%,均高于单独诊断,差异有统计学意义（P〈0.05）。结论：彩色多普勒高频超声与血清肿瘤标志物联合诊断小乳腺癌的灵敏度、特异性和准确率较高,具有较高的临床诊断价值。     

全数字化乳腺X线摄影联合彩色多普勒超声对诊断微小乳腺癌的研究

目的 探讨全数字化乳腺X线摄影联合彩色多普勒超声(彩超)检查对微小乳腺癌的诊断价值.方法 66例直径≤1.5 cm的微小乳腺癌患者(恶性组)和20例直径≤1.5 cm的乳腺良性病变患者(良性组)均行全数字化乳腺X线摄影和彩超检查,进行定性诊断,最后与手术病理结果对照.结果 恶性组:全数字化乳腺X线摄影诊断微小乳腺癌55例,其敏感度和特异度分别为83.3%(55,66)、90.0%(18/20),准确度为84.9%(73,86);彩超诊断微小乳腺癌52例,其敏感度和特异度分别为78.8%(52/66)、75.0%(15/20),准确度为77.9%(67/86);二者联合诊断微小乳腺癌65例,其敏感度和特异度分别为98.5%(65/66)、100.0%(20/20),准确度为98.8%(85/86).与单一检查比较差异有统计学意义(P＜0.05).恶性组收缩期峰值流速及血流阻力指数均高于良性组,差异有统计学意义(P＜0.05).结论 对微小乳腺癌定性诊断方面,全数字化乳腺X线摄影为首选,彩超对良恶性结节鉴别诊断有一定帮助,二者联合应用可提高微小乳腺癌的检出率和准确度.     

彩超、X线钼靶及两法联合诊断乳腺癌的价值

目的探讨彩超、X线钼靶及两法联合应用在乳腺癌诊断中的价值。方法对怀疑乳腺癌的127个乳腺小肿块(d≤2 cm)行彩超及X线钼靶检查,将检查结果与病理结果进行比较,并对彩超、X线钼靶及两法联合应用的效果进行分析。结果彩超、X线钼靶及两法联合符合率分别是69.29%、66.93%和92.91%,差异有统计学意义(p<0.05);两法联合对BI-RDSAⅢ-Ⅳ的灵敏度较高,可靠性和准确性更大。结论彩超、X线钼靶及两法联合是诊断乳腺癌可行的方法,但彩超和X线钼靶联合应用的灵敏度及符合率更高,具有较高临床价值。     

应用钼靶和彩超联合诊断乳腺癌的价值

目的:探讨应用乳腺数字钼靶(钼靶)和彩色多普勒超声(彩超)联合诊断乳腺癌的新进展和临床应用的价值。方法:收集了2008～2011年近4年来的136例经病理证实的乳腺癌患者的临床资料,分析乳腺钼靶和彩超的各自影像特点、鉴别诊断各自的优势及联合诊断乳腺癌的重要意义。结果:单独运用钼靶和彩超的乳腺癌诊断符合率分别为90.44%和82.35%,而联合诊断符合率可高达94.12%(128/136)。结论:在乳腺癌的诊断过程中,钼靶和彩超均为诊断乳腺癌的首选方法,两者联合应用对提高乳腺癌诊断的敏感性、准确性均有较高价值。     

彩色多普勒超声结合弹性成像对判定乳腺小结节良恶性的诊断价值

目的分析彩色多普勒超声结合弹性成像在诊断乳腺小结节良恶性中的应用价值。方法回顾性分析经病理证实的127枚乳腺小结节病灶,分别分析彩色多普勒超声结合弹性成像与X线钼靶检查两种检查方法在乳腺小结节病灶的诊断符合情况。结果彩色多普勒超声结合弹性成像对乳腺小结节病灶良恶性诊断敏感性、特异性、准确性分别为75.0%(21/28)、92.3%(92/99)、89.0%(113/127);X线钼靶对乳腺小结节病灶良恶性诊断敏感性、特异性、准确性分别为60.7%(17/28)、94.9%(94/99)、87.4%(111/127)。结论彩色多普勒超声结合弹性成像对乳腺小结节病灶的良恶性诊断具有较高的敏感性和特异性,可以弥补钼靶X线对乳腺小结节病灶诊断的不足。     

彩色多普勒超声和钼靶X线诊断小乳腺癌的临床价值比较

目的：比较彩色多普勒超声、钼靶X线对小乳腺癌的诊断价值。方法：回顾分析经手术病理证实的92例小乳腺癌患者（114个病灶）的彩色多普勒超声和钼靶X线资料特征,比较二者分别诊断小乳腺癌的灵敏度及特异性。结果：超声检查小乳腺癌的灵敏度为86．18％,特异性为64．10％,假阴性率为4．52％;钼靶X线检查小乳腺癌的灵敏度为82．25％,特异性为90．37％,假阴性率为8．97％,二者之间的差异具有统计学意义（P〈0．05）。钼靶X线对微小钙化的显示优于超声（P〈0．05）,钼靶X线对多灶性小乳癌的检出率明显高于超声。结论：钼靶X线及彩色多普勒超声在发现和诊断小乳腺癌上均具有重要价值,两者结合可进一考据高小乳腺痛的枪出率和论断台白缝确率。     

X线钼靶与超声诊断乳腺疑似病变价值比较

目的 评价并比较X线钼靶和乳腺超声用于乳腺疑似病变的诊断效能。方法 以经X线钼靶或乳腺超声诊断的80例女性疑似乳腺病变患者作为研究对象,以组织病理学检测结果作为金标准,计算并比较X线钼靶和乳腺超声检测乳腺病变的灵敏度、特异度、阳性预测值（PPV）、阴性预测值（NPV）及准确度。结果 80例疑似女性乳腺病变患者中,经组织病理学检查确诊乳腺癌57例、乳腺良性病变23例。X线钼靶诊断疑似女性乳腺病变灵敏度、特异度、NPV、PPV和准确度分别为63.16%、73.91%、44.74%、85.71%和66.25%,乳腺超声诊断疑似女性乳腺病变灵敏度、特异度、NPV、PPV和准确度分别为78.95%、21.74%、29.41%、71.43%和62.50%。X线钼靶和乳腺超声诊断疑似女性乳腺病变灵敏度（χ² = 3.45,P > 0.05）、NPV（χ² = 1.15,P > 0.05）、PPV（χ² = 2.92,P > 0.05）、准确度（χ² = 0.25,P > 0.05）差异均无统计学意义,但两者检测特异度差异有统计学意义（χ² = 12.55,P < 0.01）。结论 X线钼靶和乳腺超声用于疑似女性乳腺病变诊断准确度类似,但X线钼靶诊断疑似女性乳腺病变特异度明显高于乳腺超声。     

研究血清多种肿瘤标志物联合检测在肺癌诊断中的价值

目的：研究血清多种肿瘤标志物联合检测在肺癌诊断中的价值,寻找最为有效的肺癌诊断方式。方法：选取自2012年5月-2013年12月入住本院的200例肺癌患者进行癌胚抗原（CEA）、糖类抗癌原199（CA19-9）、糖类癌抗原125（CA125）、神经元特异性烯醇化酶（NSE）和细胞角蛋白片段19（CYFRA21-1）等5个项目的敏感度、准确性和特异度检测。血清癌胚抗原（CEA）、细胞角蛋白片段19（CYFRA21-1）、神经元特异性烯醇化酶（NSE）、糖类抗癌原199（CA19-9）和糖类抗癌抗原125（CA125）均采用化学发光法进行检测,将检测的结果进行统计学数据处理。结果：细胞角蛋白片段19（CYFRA21-1）在单个项目的检测中肺癌诊断的敏感度和准确性最高为（64%和75.6%）,然而特异度却是糖类抗癌原199（CA19-9）以（98.8%）排在首位。与单个项目的检测数据相对比联合检测的敏感度和准确性都有着明显的提高,以神经元特异性烯醇化酶（NSE）和细胞角蛋白片段19（CYFRA21-1）（83.6%和82.9%）排在第一,特异度则以糖类癌抗原125（CA125）和糖类抗癌原199（CA19-9）（97.6%）最高。结论：通过结果显示联合检测在肺癌诊断中的敏感度、准确性都有着明显的提高,极大的提高的肺癌诊断的准确率,可以广泛的应用于临床中。